Company intelligence / Profile preview

Inoviv

London, England, United Kingdominoviv.com ↗

Ownership: Private
Development stage: Commercial

Overview

Inoviv has developed proprietary mass spectrometry-based workflows enabling highly accurate, fully quantitative multiplexed biomarker analysis. Their technology supports pharmaceutical and biotech companies in clinical trial patient stratification, treatment monitoring, and mechanistic studies. The company’s panels can measure 50+ calibrated biomarkers per sample with high reproducibility across thousands of samples. Recent funding is accelerating expansion into new disease areas such as neurology, fibrosis, and oncology.

Modalities: Diagnostic assayProteomics platform
Industry: Protein Biomarker Diagnostics

Partnerships

Not specifically disclosed; works with leading pharmaceutical companies globally.

Beyond the preview

Go deeper on Inoviv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inoviv.

Explore the full profile